

主旨: 轉寄: [WARNING: MESSAGE ENCRYPTED]FDA FMD145 EIR - Chunghwa Chemical  
Synthesis & Biotech Co., Ltd - FEI: 3002806677

---

寄件者: <atul.agrawal@fda.hhs.gov>  
收件者: <Patrick.wei@ccsb.com.tw>, <atul.agrawal@fda.hhs.gov>,  
<rita.kabaso@fda.hhs.gov>  
日期: 2023/01/14 上午 02:31  
主旨: [WARNING: MESSAGE ENCRYPTED]FDA FMD145 EIR - Chunghwa Chemical Synthesis &  
Biotech Co., Ltd - FEI: 3002806677

---

Dear Ching Peng (Patrick) Wei:

Attached to this email is a copy of the establishment inspection report (EIR) for the inspection completed at your establishment located at Shu-Lin District, 1 Tung-Hsing Street, New Taipei City, Taipei conducted on 11/18/2022 by or on behalf of the U.S. Food and Drug Administration (FDA). **The Agency concluded that the inspection is "closed"** under [21 C.F.R.20.64\(d\)\(3\)](#), and therefore is releasing a copy of the EIR to you.

The copy provided to you is the narrative portion of the report. It may contain redactions in accordance with the Freedom of Information Act (FOIA) and [21 CFR part 20](#). You may request additional information under FOIA. For more information on how to make a FOIA request [click here](#)

The attached EIR is password protected to secure your firm's proprietary information and/or trade secrets. The password needed to open and/or print the document will be forwarded to you in a separate e-mail. You may need to check your Spam folder if you do not see the password in your e-mail inbox. If you did not receive the password in a separate e-mail, please contact the POC below.

If you have any questions regarding this letter, you may contact Atul J. Agrawal or Rita K Kabaso via email at [atul.agrawal@fda.hhs.gov](mailto:atul.agrawal@fda.hhs.gov) or [rita.kabaso@fda.hhs.gov](mailto:rita.kabaso@fda.hhs.gov), respectively.

Sincerely,

Atul J. Agrawal  
Division Director  
Division of Foreign Pharmaceutical Quality Inspections

## TABLE OF CONTENTS

Summary .....	2
Administrative Data .....	3
History .....	3
Interstate Commerce .....	3
Jurisdiction.....	4
Individual Responsibility and Persons Interviewed.....	4
Firm's Training Program.....	4
Manufacturing/Design Operations.....	5
Manufacturing Codes .....	7
Complaints.....	7
Recall Procedures.....	7
Objectionable Conditions and Management's Response .....	7
Refusals .....	9
General Discussion with Management .....	9
Additional Information.....	11
Samples Collected .....	11
Voluntary Corrections .....	11
Exhibits Collected.....	11
Attachments .....	11